Preventing Antimicrobial Resistance in Hospitals: Infection Control and Antibiotic Use

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotic Therapy in Infectious Diseases".

Deadline for manuscript submissions: 20 March 2025 | Viewed by 1001

Special Issue Editors


E-Mail Website
Guest Editor
Laboratory Medical Immunology, Department of Microbiology, Medical University of Lodz, Ul. Pomorska 251/C5, 92-213 Lodz, Poland
Interests: molecular microbiology; mechanisms of antimicrobial resistance; antibiotic resistance genes (ARGs); AMR control-ling methods

E-Mail Website
Guest Editor
Laboratory Medical Immunology, Department of Microbiology, Medical University of Lodz, Ul. Pomorska 251/C5, 92-213 Lodz, Poland
Interests: urinary tract infection; antimicrobials; nitrofuran derivatives; antimicrobial stewardship; antimicrobial susceptibil-ity testing; antimicrobial synergy

E-Mail Website
Guest Editor
1. Laboratory Medical Immunology, Department of Microbiology, Medical University of Lodz, Ul. Pomorska 251/C5, 92-213 Lodz, Poland
2. Medical Microbiology Laboratory, Central Teaching Hospital of Medical University of Lodz, Lodz, Poland
Interests: multidrug resistance; antimicrobials; carbapenem resistance; antimicrobial stewardship; antimicrobial susceptibil-ity testing; antimicrobial synergy

Special Issue Information

Dear Colleagues,

The growing issue of antimicrobial resistance (AMR) poses one of the most formidable challenges to public health. Hospitals, where most patients reside and where antimicrobial agents are most frequently used, are critical places in this silent pandemic. Central to this crisis is the intricate balance between the necessity of antibiotic use and the imperative to minimize the development of resistance.

In this Special Issue, we aim to delve into the multifaceted strategies required to combat AMR within healthcare settings. Our aim is to explore this balance and offer insights into effective infection control practices, stewardship programs, and innovative approaches to antibiotic use. Key topics include, but are not limited to, the following:

  • Infection Control Measures: Highlighting the critical importance of hygiene practices, surveillance systems, and outbreak management protocols and underscoring infection prevention guidelines to curb the spread of resistant pathogens within hospitals.
  • Optimizing Antibiotic Use: Presenting evidence-based strategies, including the implementation of stewardship programs, education and training of healthcare professionals, and the development of policies that promote the judicious use of antimicrobials.
  • Research and Technological Advancements: Bringing attention to cutting-edge research and technological advancements that promise to enhance our ability to detect, monitor, and combat AMR. This includes rapid diagnostic tools for the precise and timely identification of pathogens, as well as the development of new antimicrobial agents and alternative therapies.
  • Understanding AMR: Investigating the mechanisms, causes, and consequences of clinical antimicrobial resistance to develop effective strategies to mitigate its impact.

We look forward to receiving your contributions.

Prof. Dr. Dorota Pastuszak-Lewandoska
Dr. Filip Bielec
Dr. Małgorzata Brauncajs
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • clinical antibiotic use
  • hospital infection control
  • healthcare-associated infections
  • resistance mitigation strategies
  • alternative therapies
  • antibiotic stewardship
  • molecular mechanisms of AMR
  • new therapeutic combinations of antibiotics
  • antimicrobial synergy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 513 KiB  
Article
Clostridioides difficile Infection: Use of Inflammatory Biomarkers and Hemogram-Derived Ratios to Predict Mortality Risk in Hospitalized Patients
by Giuseppe Guido Maria Scarlata, Angela Quirino, Carmen Costache, Dan Alexandru Toc, Nadia Marascio, Marta Pantanella, Daniel Corneliu Leucuta, Abdulrahman Ismaiel, Dan Lucian Dumitrascu and Ludovico Abenavoli
Antibiotics 2024, 13(8), 769; https://doi.org/10.3390/antibiotics13080769 - 15 Aug 2024
Viewed by 840
Abstract
Background: Clostridioides difficile infection (CDI) is a significant cause of mortality, especially in healthcare environments. Reliable biomarkers that can accurately predict mortality in CDI patients are yet to be evaluated. Our study aims to evaluate the accuracy of several inflammatory biomarkers and hemogram-derived [...] Read more.
Background: Clostridioides difficile infection (CDI) is a significant cause of mortality, especially in healthcare environments. Reliable biomarkers that can accurately predict mortality in CDI patients are yet to be evaluated. Our study aims to evaluate the accuracy of several inflammatory biomarkers and hemogram-derived ratios in predicting mortality in CDI patients, such as the neutrophil-to-lymphocyte ratio (NLR), the systemic immune-inflammation index (SII), the platelet-to-neutrophil ratio (PNR), the derived neutrophil-to-lymphocyte ratio (dNLR), C-reactive protein (CRP), the platelet-to-lymphocyte ratio (PLR), and procalcitonin (PCT). Results: NLR showed a sensitivity of 72.5% and a specificity of 58.42% with an area under curve (AUC) = 0.652. SII had a sensitivity of 77.5%, a specificity of 54.74%, and an AUC = 0.64. PNR, neutrophils, dNLR, and lymphocytes had lower AUCs which ranged from 0.595 to 0.616, with varied sensitivity and specificity. CRP, leukocytes, and platelets showed modest predictive values with AUCs below 0.6. PCT had a sensitivity of 100%, a low specificity of 7.41%, and an AUC = 0.528. Methods: We conducted a retrospective analysis of CDI patients from two different hospital settings in Italy and Romania during the COVID-19 pandemic, from 1 January 2020 to 5 May 2023. Statistical analyses included t-tests, Wilcoxon rank-sum tests, χ2 tests, and multivariate logistic regression to identify predictors of mortality. ROC analysis assessed the accuracy of biomarkers and hemogram-derived ratios. A p value < 0.05 was considered significant. Conclusions: Neutrophils, dNLR, NLR, SII, and PNR are valuable biomarkers for predicting mortality in CDI patients. Understanding these predictors can improve risk stratification and clinical outcomes for CDI patients. Full article
Show Figures

Figure 1

Back to TopTop